ENBREL is the #1 prescribed biologic by rheumatologists*1
ENBREL is an anti-tumor necrosis factor biologic medication indicated for the treatment of moderate to severe rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis, and moderately to severely active polyarticular juvenile idiopathic arthritis.4
The experience of ENBREL is well established
- Evaluated in RA clinical studies since 1993†2
- 15 years of postmarketing use in moderate to severe RA since approval in 19983
- Over 25,000 patients have been observed across 70 clinical studies‡4
- More than 35,000 patient-years of therapy in clinical studies across indications‡5
A History of "1sts" Among Biologics in Each of Its Indications††
approved for moderate to severe RA in DMARD**
approved for moderately to severely active polyarticular juvenile RA (JRA)6††
approved for psoriatic arthritis7††
approved for ankylosing spondylitis (AS)8††
approved for moderate to severe plaque psoriasis9††‡‡
TNF inhibitor with a decade of post-marketing experience in RA10
* 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts.
† Initial clinical research in RA patients began in 1993.
‡ Patients observed for safety across all indications. Includes global clinical trials and 4 cohort studies in the U.S. and Canada.
** DMARD = disease-modifying antirheumatic drug.
†† First tumor necrosis factor (TNF) inhibitor approved in the United States.
‡‡ Chronic moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
In medical studies, ENBREL was shown to be clinically effective in about 2 out of 3 adults with moderate to severe RA at 3 months. ENBREL has been shown to begin working in as few as 2 weeks, and most patients who benefit will do so within 3 months. In another medical study, 55% of patients who were evaluated 5 years after beginning ENBREL therapy had no further progression of joint damage.
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.